JP2022551254A5 - - Google Patents
Info
- Publication number
- JP2022551254A5 JP2022551254A5 JP2022520234A JP2022520234A JP2022551254A5 JP 2022551254 A5 JP2022551254 A5 JP 2022551254A5 JP 2022520234 A JP2022520234 A JP 2022520234A JP 2022520234 A JP2022520234 A JP 2022520234A JP 2022551254 A5 JP2022551254 A5 JP 2022551254A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- salt according
- following
- alkyl
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962908715P | 2019-10-01 | 2019-10-01 | |
| US62/908,715 | 2019-10-01 | ||
| US201962925300P | 2019-10-24 | 2019-10-24 | |
| US62/925,300 | 2019-10-24 | ||
| PCT/IB2020/059103 WO2021064571A1 (en) | 2019-10-01 | 2020-09-29 | N-substituted-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl derivatives as inhibitors of the human immunodeficiency virus replication |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022551254A JP2022551254A (ja) | 2022-12-08 |
| JP2022551254A5 true JP2022551254A5 (cg-RX-API-DMAC7.html) | 2023-10-10 |
Family
ID=72811913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022520234A Pending JP2022551254A (ja) | 2019-10-01 | 2020-09-29 | ヒト免疫不全ウイルスの複製阻害剤 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20220389007A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4038068A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022551254A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021064571A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA53973A (fr) | 2018-10-24 | 2022-02-09 | Viiv Healthcare Uk No 5 Ltd | Inhibiteurs de la réplication du virus de l'immunodéficience humaine |
| TW202128648A (zh) * | 2019-10-04 | 2021-08-01 | 英商Viiv醫療保健英國(No 5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| WO2021070054A1 (en) * | 2019-10-08 | 2021-04-15 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| TW202448483A (zh) | 2023-05-31 | 2024-12-16 | 美商基利科學股份有限公司 | 用於hiv之治療性化合物 |
| AR132951A1 (es) | 2023-06-15 | 2025-08-13 | Viiv Healthcare Uk No 5 Ltd | Métodos e intermedios para preparar compuestos |
| WO2025169059A1 (en) | 2024-02-05 | 2025-08-14 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102464654B (zh) | 2010-11-12 | 2016-01-13 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| CA2840095A1 (en) | 2011-07-06 | 2013-01-10 | Gilead Sciences, Inc. | Compounds for the treatment of hiv |
| CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| US9220710B2 (en) | 2013-01-09 | 2015-12-29 | Gilead Sciences, Inc. | Therapeutic compounds |
| EP2943493B1 (en) | 2013-01-09 | 2017-08-02 | Gilead Sciences, Inc. | Therapeutic compounds for the treatment of viral infections |
| TW201443037A (zh) * | 2013-01-09 | 2014-11-16 | Gilead Sciences Inc | 治療用化合物 |
| TWI694071B (zh) | 2013-03-01 | 2020-05-21 | 美商基利科學股份有限公司 | 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物 |
| WO2015130966A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Antiviral agents |
| WO2015130964A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Therapeutic compounds |
| US9873680B2 (en) | 2014-08-29 | 2018-01-23 | Gilead Sciences, Inc. | Therapeutic compounds |
| LT3347352T (lt) | 2016-08-19 | 2019-08-12 | Gilead Sciences, Inc. | Terapiniai junginiai, naudotini živ viruso infekcijos profilaktikai arba terapiniam gydymui |
| TW201906834A (zh) | 2017-05-02 | 2019-02-16 | 英商Viiv醫療保健英國(No.5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| WO2019161017A1 (en) | 2018-02-15 | 2019-08-22 | Gilead Sciences, Inc. | Pyridine derivatives and their use for treating hiv infection |
| KR102847339B1 (ko) | 2018-02-16 | 2025-08-19 | 길리애드 사이언시즈, 인코포레이티드 | 레트로비리다에 바이러스 감염의 치료에 유용한 치료 화합물을 제조하기 위한 방법 및 중간체 |
-
2020
- 2020-09-29 EP EP20789277.9A patent/EP4038068A1/en not_active Withdrawn
- 2020-09-29 JP JP2022520234A patent/JP2022551254A/ja active Pending
- 2020-09-29 WO PCT/IB2020/059103 patent/WO2021064571A1/en not_active Ceased
- 2020-09-29 US US17/763,133 patent/US20220389007A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100396682C (zh) | 用于制备喜树碱衍生物(cpt-11)以及相关化合物的中间体和方法 | |
| JP6392436B2 (ja) | 置換された5−フルオロ−1h−ピラゾロピリジン類を製造するための方法 | |
| JP2022552156A5 (cg-RX-API-DMAC7.html) | ||
| CN113490668B (zh) | 用于治疗与apj受体活性有关的疾病的化合物和组合物 | |
| JP7744955B2 (ja) | 可溶性グアニル酸シクラーゼ刺激剤を調製するための新規のプロセスおよび中間体 | |
| CN107709298A (zh) | 作为溴结构域抑制剂的螺[环丁烷‑1,3’‑二氢吲哚]‑2’‑酮衍生物 | |
| JP2023517043A5 (cg-RX-API-DMAC7.html) | ||
| AP805A (en) | Process for substituted pyridines. | |
| TW202233614A (zh) | 作為激酶抑制劑之三唑并吡啶化合物 | |
| JPWO2016121777A1 (ja) | ピラジンカルボキサミド化合物の製造方法及びその合成中間体 | |
| KR102477924B1 (ko) | 인돌 카르복스아미드 화합물을 제조하는 방법 | |
| TWI884151B (zh) | 製備4-苯基-5-烷氧基羰基-2-噻唑-2-基-1,4-二氫嘧啶-6-基]甲基]-3-側氧-5,6,8,8a-四氫-1H-咪唑并[1,5-a]吡-2-基]-羧酸之替代方法 | |
| JP2025510230A (ja) | Shp2阻害剤の調製プロセス | |
| TW202229251A (zh) | 乙醯胺基-苯基苯甲醯胺衍生物及其使用方法 | |
| EP4538259A1 (en) | Processes for the preparation of deucravacitinib | |
| WO2025245089A1 (en) | Processes for preparing tetralin compounds | |
| CN116745282A (zh) | 抑制2-羟环烷-1-氨甲酰基衍生物的半乳糖凝集素-3 | |
| EP3560927A1 (en) | Azepine derivative acting as 5-ht7 receptor modulator | |
| JP2005535595A (ja) | 4−ハロアルキルニコチン酸アミドの製造 |